In patients with type 2 diabetes and preserved renal function treatment with M+I resulted in reduction of renal perfusion and increase in vascular resistance, in contrast to treatment with E+I that preserved renal perfusion and reduced vascular resistance (Cardiovascular Diabetology)
Diabetes News
Category: Nephropathy
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial
Among patients treated with renin–angiotensin–aldosterone system inhibitors, SGLT2 inhibition with canagliflozin may reduce the risk of hyperkalaemia in people with T2DM and CKD without increasing the risk of hypokalaemia (European Heart Journal)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
GLP-1 receptor agonists, regardless of structural homology, reduced the risk of individual MACE components, all-cause mortality, hospital admission for heart failure, and worsening kidney function in patients with type 2 diabetes (The Lancet Diabetes & Endocrinology)
Glycemic Variability and KIM-1–Induced Inflammation in the Diabetic Kidney
Recognition of DKD as an inflammatory disease linked by metabolic perturbations and immune responses is a central tenet that requires broader and deeper exploration (Diabetes)
Effect of Mineralocorticoid Receptor Antagonism and ACE Inhibition on Angiotensin Profiles in Diabetic Kidney Disease: An Exploratory Study
Combined eplerenone and ACEi therapy increases Ang-(1–7) levels in patients with CKD indicating a unique nephroprotective RAAS pattern with considerable therapeutic implications (Diabetes Therapy)
SGLT2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation
Dapagliflozin prevented the progression of diabetic kidney disease by inhibiting cellular senescence and oxidative stress via ketone-induced NRF2 activation (Diabetes, Obesity and Metabolism)
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
Lower plasma BNP level and the use of RASI at baseline were the key factors contributing to the renoprotective effects of SGLT2i among patients with decompensated HF and T2DM (BMC Cardiovascular Disorders)
Relationship Between the TyG Index and Diabetic Kidney Disease in Patients with Type-2 Diabetes Mellitus
The TyG Index is a potential predictor for DKD in T2DM patients (Metabolic Syndrome and Obesity)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo (NEJM)
Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes
In this trial involving participants with type 2 diabetes who had either a history of cardiovascular disease or current kidney disease plus at least one other cardiovascular risk factor, the risk of cardiovascular events was lower among those who received weekly subcutaneous injections of efpeglenatide at a dose of 4 or 6 mg than among those who received placebo (NEJM)
TIMP3 involvement and potentiality in the diagnosis, prognosis and treatment of diabetic nephropathy
Several recent evidences point to TIMP3 as a potential biomarker or therapeutic target for kidney diabetic disease. Given the multiplicity of TIMP3 actions it is plausible that is more appropriate to rescue its level in vivo to obtain a therapeutic effect rather than trying to inhibit all the enzymes or receptors that are overactivated in its absence (Acta Diabetologica)
Burden of chronic kidney disease and rapid decline in renal function among adults attending a hospital-based diabetes center in Northern Europe
DKD (using the KDIGO 2012 classification) and rapid eGFR decline were highly prevalent among adults attending a hospital-based diabetes clinic in a predominantly Caucasian Northern European country. The burden was greater for adults with type 2 diabetes. Expected as well as potentially novel clinical predictors were identified (BMJ)
Meta-Analysis of the Relationship between Abdominal Obesity and Diabetic Kidney Disease in Type 2 Diabetic Patients
In this meta-analysis, we found abdominal obesity parameters (continuous VFA, WC) were associated with increased odds of DKD, and type 2 diabetic patients with DKD were more likely to have abdominal obesity (Karger International)
Serum albumin modifies the effect of peripheral blood monocytes on severity of diabetic nephropathy
Circulating monocytes and serum albumin are significantly associated with albuminuria, but not eGFR in DKD. These results support the potential role of the innate immune system in diabetic microvascular end-organ damage and urine protein loss, and may be readily translatable clinical markers to incorporate into risk-assessment models for prognostication in diabetes (Canadian Journal of Diabetes)
Circulating short and medium chain fatty acids are associated with normoalbuminuria in type 1 diabetes of long duration
Our findings suggest that MCFAs and SCFAs contribute to the metabolic processes underlying protection against albuminuria development in T1D that are independent from mechanisms associated with changes in renal function (Nature)
Deficits in the Skeletal Muscle Transcriptome and Mitochondrial Coupling in Progressive Diabetes-Induced CKD Relate to Functional Decline
Our results indicate that T2DM-induced CKD progression impairs physical function, with implications for altered metabolic transcriptional networks and mitochondrial functional deficits as primary mechanistic factors early in CKD progression in T2DM (Diabetes)
Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co‐Transporter‐2 Compared to Dipeptidyl Peptidase‐4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease
SGLT2i were associated with reduced risk of all–cause mortality and hospitalisation for HF and CKD compared with DPP4–i, highlighting the need to introduce SGLT2i early in the management of T2D patients (Diabetes, Obesity and Metabolism)
Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes
Medications shown to slow progression of CKD include renin–angiotensin system inhibitors, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists and, more recently, non-steroidal mineralocorticoid receptor antagonists (Diabetes Therapy)
Association of genetic variants for plasma LRG1 with rapid decline in kidney function in patients with type 2 diabetes
We demonstrate that genetically influenced plasma LRG1 increases the risk of RDKF in T2D patients suggesting plasma LRG1 as a potential treatment target. However, further studies are warranted to elucidate underlying pathways to provide insight into DKD prevention (Journal of Clinical Endocrinology & Metabolism)
Development of a sensitive and reliable ELISA kit of urinary haptoglobin to predict progress of diabetic kidney disease
We have generated an ELISA kit to accurately detect UHp levels, which is potentially a reliable biomarker of DKD (Diabetes/Metabolism Research and Reviews)
- 1
- 2
- 3
- …
- 6
- Next Page »
Glycosmedia is also available as an App: